Is rosacea a risk factor for cancer: A population-based cohort study in Taiwan

Autor: Tsung-Hsien Chang, Hsiu J Ho, Yun-Ting Chang, Chung-Pin Li, Chun-Ying Wu, Chen-Yi Wu

Publikováno v: Dermatologica Sinica, Vol 38, Iss 1, Pp 15-21 (2020)

Background: Rosacea is a chronic inflammatory skin disease with mounting evidence associating it with systemic disorders. Cancer, induced or facilitated by chronic inflammatory microenvironment, shares common pathogenic mechanisms with rosacea. Objec

Externí odkaz: https://doaj.org/article/5d7ecfbced67457ca11e48c6b571e097

Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma

Autor: Chi-Shuan Fan, Li-Li Chen, Tsu-An Hsu, Chia-Chi Chen, Kee Voon Chua, Chung-Pin Li, Tze-Sing Huang

Publikováno v: Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-15 (2019)

Abstract Background Endothelial-to-mesenchymal transition (EndoMT) can provide a source of cancer-associated fibroblasts which contribute to desmoplasia of many malignancies including pancreatic ductal adenocarcinoma (PDAC). We investigated the clini

Externí odkaz: https://doaj.org/article/128322e6f9874b66ba4efbc98bb54f5e

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Autor: Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard Epstein, Paul Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall Tebbutt, Gerald Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp-Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean-Luc Van Laethem, Stéphanie Laurent, Neesha Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke Parner, Tapio Salminen, Leena-Maija Soveri, Eija Korkeila, Pia Osterlund, Julien Taieb, David Tougeron, Pascal Artru, François Xavier Caroli-Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus-Alexander Wörns, Holger Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balazs Juhasz, László Landherr, Tamas Pinter, György Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek Power, Luca Gianni, Salvatore Siena, Michele Milella, Alfredo Falcone, Rossana Berardi, Cinzia Bagalà, Francesco Di Costanzo, Fausto Roila, Andrea Ardizzoni, Evaristo Maiello, Silvia Fanello, Johanna Wilmink, Jan Willem de Groot, Geert Creemers, Eduardo Barroso, Tânia Rodrigues, Cristina Sarmento, Cheng Ean Chee, David Tai, Teresa Macarulla Mercade, Manuel Hidalgo Medina, Alfredo Carrato Mena, Joan Maurel Santasusana, Maria Jose Flor Oncala, Carlos Gomez Martin, Rafael Lopez, Andres Muñoz, Ruth Vera Garcia, Inmaculada Ales, Berta Laquente Sáez, Fernando Rivera, Javier Sastre, Cheng-Chung Wu, Yu-Wen Tien, De-Chuan Chan, Tsann-Long Hwang, Jeffry Evans, Jonathan Wadsley, Pippa Corrie, Andrew Biankin, Andrew Ko, Dana Cardin, Elena Chiorean, Johanna Bendell, Anne Noonan, Hedy Kindler, Nishan Fernando, Muhammad Beg, Thomas George, Marcus Noel, Noelle LoConte, Francis Arena, James Posey, Rajat Malhotra, Charles Lopez, Davendra Sohal, Robert McWilliams, Warren Brenner, Mark Womack, Rahul Seth, Renuka lyer, Nathan Bahary, Robert Marsh, Robert Ramirez, Cynthia Chua, James Reeves, Gulam Manji, Anthony El-Khoueiry, Robert Weaver, Vaibhav Sahai, Wells Messersmith, Robert Dreicer, Ahmed Zakari, Andrea Bullock, Benjamin Musher, Mitesh Borad, Edward Kim, David Bajor, Tim Huyck, Hassan Hatoum, Henry Xiong, Boris Pasche, Jill Lacy, Olugbenga Olowokure, Allen Cohn, Donald Richards, Robert Martin, Andrew Paulson, Paul Fanta, Smitha Krishnamurthi, Paul Oberstein, Jyotsna Fuloria

Publikováno v: Scientia

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192d001f322850ad486a84bac981c740
https://lirias.kuleuven.be/handle/20.500.12942/715374

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Autor: Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem

Publikováno v: Scientia

Adenocarcinoma; Napabucasin; Pancreatic cancer Adenocarcinoma; Napabucasin; Càncer de pàncrees Adenocarcinoma; Napabucasin; Cáncer de páncreas Background Compared with normal cells, tumour cells contain elevated levels of reactive oxygen species

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ae2589e07e98d75566bdc3da56cba0
https://hdl.handle.net/11351/9288

A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study

Autor: Yung-Yeh Su, Yen-Feng Chiu, Chung-Pin Li, Shih-Hung Yang, Johnson Lin, Shyh-Jer Lin, Ping-Ying Chang, Nai-Jung Chiang, Yan-Shen Shan, Hui-Ju Ch’ang, Li-Tzong Chen

Publikováno v: Br J Cancer

BACKGROUND: The objective of this study was to evaluate the efficacy and safety of induction chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) versus modified FOLFIRINOX (irinotecan, oxaliplatin plus 5-FU/leucovo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a954c15bfd4091c777705d84f034fc
https://doi.org/10.1038/s41416-021-01649-7